BioXcel Therapeutics
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2017-01-01
- Employees
- 74
- Market Cap
- $26.8M
- Introduction
BioXcel Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of artificial intelligence solutions in neuroscience and immuno-oncology. It also focuses on utilizing technology and research to develop therapeutics solutions. The company was founded by Vimal D. Mehta on March 29, 2017 and is headquartered in New Haven, CT.
Transmucosal Drug Delivery Pipeline Report 2024 - Stages of
The 'Transmucosal Drug Delivery Pipeline Report 2024 Update' from ResearchAndMarkets.com offers comprehensive insights into pipeline products, clinical trials, and key companies involved in Transmucosal Drug Delivery.
BioXcel Therapeutics Advances Pivotal Phase 3 Trials of
BioXcel Therapeutics announces clinical and regulatory progress for Phase 3 trials of BXCL501 for acute agitation in bipolar disorders/schizophrenia (SERENITY At-Home) and Alzheimer’s dementia (TRANQUILITY In-Care), with no FDA-approved acute therapies for these conditions.
AI In Precision Medicine Market : Future Industry Scope, Growth
AI In Precision Medicine Market to grow at a High CAGR from 2024-2031, driven by AI's ability to tailor treatments based on genetic, environmental, and lifestyle factors. Key players include IBM, Microsoft, AstraZeneca, and Siemens Healthineers. Market segments include technology, component, application, and region.
Bioxcel Therapeutics Earns Buy Rating on Promising Clinical Trials and Market Potential
Ram Selvaraju, H.C. Wainwright analyst, maintains Buy rating on Bioxcel Therapeutics (BTAI) with $7.00 price target, citing SERENITY At-Home Phase 3 trial initiation for BXCL501, IGALMI's post-marketing study success, and FDA's positive review of SERENITY protocol. Canaccord Genuity also reiterates Buy rating with $7.00 target.
© Copyright 2025. All Rights Reserved by MedPath